Bioactivity:

Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs (IC50: 8-13 nM), less potent to EGFR, InsR, EphA2, c-Met, IGF-1R, Tie2, and HER

CAS nr:

405169-16-6

Purity:

98%

Molecular Weight:

392,43

SMILES:

CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O

Formula:

C21H21FN6O

Pathway:

Angiogenesis,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors,Tyrosine Kinase/Adaptors

Target:

PDGFR,PDGFR,FLT,FLT,VEGFR,VEGFR,FGFR,FGFR,c-Kit